Research & Training

ONC201 Suppresses Growth Among Cancer Cell Types

A recent preclinical investigation of a novel small molecule called ONC201, conducted in Wafik S. El-Deiry's lab, suggests it could potentially offer therapeutic benefits for patients diagnosed with either triple negative or non-triple negative breast cancer.

Caris Life Sciences® and Fox Chase Collaborate

Researchers from Caris Life Sciences® and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for new therapeutic options for triple-negative breast cancer (TNBC). 

Delaying Surgery After Diagnosis May Lower Survival Rate

Waiting too long for breast cancer treatment is associated with lower survival rates, according to research led by Richard Bleicher MD, Associate Professor in the Department of Surgical Oncology, published in the Journal of American Medical Association.